oestrogens, conjugated: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
oestrogens, conjugated: clinical details
Prescribing considerations
- Confirm that symptoms adversely affect quality of life and reassess the individual benefit-risk balance periodically.
- An intact uterus generally requires adequate progestogenic endometrial protection.
- Assess personal and family history, unexplained bleeding, cancer and thromboembolic, cardiovascular, hepatic and metabolic risk.
- Use particular caution with fibroids, endometriosis, migraine, hypertension, diabetes, gallstones, epilepsy, asthma, systemic lupus erythematosus and hypertriglyceridaemia.
- Consider perioperative thromboembolic risk when major surgery or prolonged immobilisation is expected.
Contraindications and cautions
- Known, suspected or previous breast cancer
- Known or suspected oestrogen-dependent malignancy
- Unexplained genital bleeding or untreated endometrial hyperplasia
- Previous or current venous thromboembolism or known thrombophilia
- Active or recent arterial thromboembolic disease
- Active liver disease, or previous liver disease with persistently abnormal function
- Porphyria or hypersensitivity to the product
Monitoring
- Review symptom response, adverse effects and continuing benefit-risk balance.
- Investigate persistent, heavy or newly occurring unscheduled bleeding.
- Support routine breast awareness and appropriate screening.
- Monitor blood pressure and relevant hepatic, metabolic, triglyceride or thyroid measures when clinically indicated.
- Guide treatment primarily by clinical response rather than serum oestradiol or gonadotrophin concentrations.
Clinical pharmacology
Oral conjugated oestrogens are absorbed after slow release from the coated formulation. Their components bind nuclear oestrogen receptors, undergo mainly hepatic metabolism and enterohepatic recirculation, and are excreted in urine as glucuronide and sulfate conjugates.
Formulation and product differences
- The selected preparation is a systemic oral sugar-coated tablet that releases conjugated oestrogens slowly over several hours.
- It contains lactose and sucrose, which matter in specific hereditary carbohydrate-intolerance disorders.
- Conjugated oestrogens are a mixture of naturally occurring oestrogen compounds rather than a single estradiol preparation.
oestrogens, conjugated interactions
Tell the prescriber or pharmacist about all medicines, supplements and herbal products.
Carbamazepine, phenytoin and phenobarbital
These enzyme-inducing antiseizure medicines may reduce oestrogen exposure, decreasing its effect or altering bleeding.
Rifampicin, rifabutin, nevirapine and efavirenz
These medicines may accelerate oestrogen metabolism and reduce treatment effect.
St John's wort
This herbal product may lower oestrogen concentrations and alter symptom control or bleeding.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.